• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Off-label prescription of BNT162b2 mRNA COVID-19 vaccine to <5-year-old children in the European Union.

作者信息

Dal-Ré Rafael, Calvo Cristina, Neth Olaf

机构信息

Epidemiology Unit, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid, Madrid, Spain.

Paediatric Infectious Diseases Department, La Paz University Hospital, IdiPaz Foundation, Madrid, Spain.

出版信息

Acta Paediatr. 2023 Feb;112(2):183-185. doi: 10.1111/apa.16442. Epub 2022 Jun 26.

DOI:10.1111/apa.16442
PMID:35657672
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9347686/
Abstract
摘要

相似文献

1
Off-label prescription of BNT162b2 mRNA COVID-19 vaccine to <5-year-old children in the European Union.欧盟对5岁以下儿童进行BNT162b2 mRNA新冠疫苗的超说明书用药处方
Acta Paediatr. 2023 Feb;112(2):183-185. doi: 10.1111/apa.16442. Epub 2022 Jun 26.
2
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in children under 5 years.BNT162b2 mRNA新冠疫苗在5岁以下儿童中的有效性。
J Clin Invest. 2023 Nov 1;133(21):e173329. doi: 10.1172/JCI173329.
3
Comparative Safety of the BNT162b2 Messenger RNA COVID-19 Vaccine vs Other Approved Vaccines in Children Younger Than 5 Years.BNT162b2 信使 RNA COVID-19 疫苗与 5 岁以下儿童中其他获批疫苗的比较安全性。
JAMA Netw Open. 2022 Oct 3;5(10):e2237140. doi: 10.1001/jamanetworkopen.2022.37140.
4
BNT162b2 mRNA COVID-19 Vaccine: First Approval.BNT162b2 mRNA COVID-19 疫苗：首次批准。
Drugs. 2021 Mar;81(4):495-501. doi: 10.1007/s40265-021-01480-7.
5
Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated COVID-19 vaccine followed by an mRNA vaccine in children aged 5-11 years.两种 mRNA COVID-19 疫苗与灭活 COVID-19 疫苗序贯加强接种在 5-11 岁儿童中的反应原性和免疫原性比较。
J Med Virol. 2023 May;95(5):e28758. doi: 10.1002/jmv.28758.
6
Why two doses of the BNT162b2 mRNA COVID-19 vaccine? A different strategy to speed up the vaccination process: single-dose of the BNT162b2 mRNA COVID-19 and other vaccines.为什么要接种两剂BNT162b2 mRNA新冠疫苗？一种加快疫苗接种进程的不同策略：单剂BNT162b2 mRNA新冠疫苗及其他疫苗。
Panminerva Med. 2022 Mar;64(1):131-132. doi: 10.23736/S0031-0808.21.04286-5. Epub 2021 Jan 22.
7
Safety of Ancestral Monovalent BNT162b2, mRNA-1273, and NVX-CoV2373 COVID-19 Vaccines in US Children Aged 6 Months to 17 Years.原始单价BNT162b2、mRNA-1273和NVX-CoV2373新冠疫苗在美国6个月至17岁儿童中的安全性。
JAMA Netw Open. 2024 Apr 1;7(4):e248192. doi: 10.1001/jamanetworkopen.2024.8192.
8
Bivalent Omicron BA.4/BA.5 BNT162b2 Vaccine in 6-Month- to <12-Year-Olds.6 月龄至<12 岁儿童接种二价奥密克戎 BA.4/BA.5 BNT162b2 疫苗。
J Pediatric Infect Dis Soc. 2024 Aug 24;13(8):421-429. doi: 10.1093/jpids/piae062.
9
Pediatric Off-Label Use of Covid-19 Vaccines: Ethical and Legal Considerations.儿科超说明书使用新冠病毒疫苗：伦理与法律考量。
Hastings Cent Rep. 2021 Nov;51(6):27-32. doi: 10.1002/hast.1296. Epub 2021 Nov 8.
10
Batch-dependent safety of the BNT162b2 mRNA COVID-19 vaccine.BNT162b2 mRNA新冠疫苗的批次依赖性安全性。
Eur J Clin Invest. 2023 Aug;53(8):e13998. doi: 10.1111/eci.13998. Epub 2023 Apr 9.

本文引用的文献

1
Household overcrowding and risk of SARS-CoV-2: analysis of the Virus Watch prospective community cohort study in England and Wales.家庭过度拥挤与新型冠状病毒2的风险：对英格兰和威尔士病毒监测前瞻性社区队列研究的分析
Wellcome Open Res. 2021 Dec 15;6:347. doi: 10.12688/wellcomeopenres.17308.1. eCollection 2021.
2
Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation.2020年12月至2021年8月美国12至20岁接种新冠病毒疫苗儿童的多系统炎症综合征报告病例：一项监测调查。
Lancet Child Adolesc Health. 2022 May;6(5):303-312. doi: 10.1016/S2352-4642(22)00028-1. Epub 2022 Feb 23.
3
Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents.更新的 COVID-19 青少年治疗中单抗治疗的使用和优先级建议。
J Pediatric Infect Dis Soc. 2022 May 30;11(5):177-185. doi: 10.1093/jpids/piab124.
4
Off-Label Prescription of COVID-19 Vaccines in Children: Clinical, Ethical, and Legal Issues.儿童 COVID-19 疫苗的标签外处方：临床、伦理和法律问题。
Pediatrics. 2022 Feb 1;149(2). doi: 10.1542/peds.2021-054578.
5
Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021.辉瑞-生物科技的 BNT162b2 (Pfizer-BioNTech) mRNA 疫苗在 12-18 岁人群中预防儿童多系统炎症综合征的有效性-美国，2021 年 7 月至 12 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 14;71(2):52-58. doi: 10.15585/mmwr.mm7102e1.
6
How Common is Long COVID in Children and Adolescents?儿童和青少年中长新冠的发病率有多高？
Pediatr Infect Dis J. 2021 Dec 1;40(12):e482-e487. doi: 10.1097/INF.0000000000003328.
7
Pediatric Off-Label Use of Covid-19 Vaccines: Ethical and Legal Considerations.儿科超说明书使用新冠病毒疫苗：伦理与法律考量。
Hastings Cent Rep. 2021 Nov;51(6):27-32. doi: 10.1002/hast.1296. Epub 2021 Nov 8.